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DESIGN AND EVALUATION OF AN INSTRUMENTED MICROFLUIDIC ORGANOTYIPC 
DEVICE AND SENSOR MODULE FOR ORGAN-ON-A-CHIP APPLICATIONS 
 
 
Organ and tissue-on-a-chip technologies are powerful tools for drug discovery and disease 
modeling, yet many of these systems rely heavily on in vitro cell culture to create reductionist 
models of tissues and organs. Therefore, Organ-on-chip devices recapitulate some tissue functions 
and are useful for high-throughput screening but fail to capture the richness of cellular interactions 
of tissues in vivo because they lack the cellular diversity and complex architecture of native tissue. 
This thesis describes the design and testing of 1) a microfluidic organotypic device (MOD) for 
culture of murine intestinal tissue and 2) a microfluidic sensor module to be implemented inline 
with the MOD for real-time sensing of analytes and metabolites. The MOD houses full-thickness 
murine intestinal tissue, including muscular, neural, immune, and epithelial components. We used 
the MOD system to maintain murine intestinal explants for 72 h ex vivo. Explants cultured in the 
MOD formed a barrier between independent fluidic channels perfused with media, which is critical 
to recapitulating intestinal barrier function in vivo. We also established differential oxygen 
concentrations in the fluidic channels and showed that more bacteria were present on the tissue’s 
mucosal surface when exposed to near-anoxic media. The sensor module is a reversibly sealed 
microfluidic device with magnetic connections that can withstand high backpressures. Further, 
electrodes housed in commercial finger-tight fittings were integrated into the sensor module in a 
plug-and-play format. Future work will include developing electrochemical/optical sensors for 
various biological compounds relevant to intestinal physiology. Ultimately, the MOD and sensor 
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module will be implemented in long-term microbiome studies to elucidate the relationship among 
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CHAPTER 1. INTRODUCTION 
1.1 Organ-on-a-Chip Technologies and Applications 
Since its advent in the early 20th century, traditional in vitro cell culture has proven to be 
instrumental in disease modeling and pharmaceutical drug development. Cell lines are typically 
cultured in static environments such as petri dishes or Transwell inserts and are utilized in areas 
ranging from cancer research to vaccine manufacturing and monoclonal antibody production.1 
Within the field of pharmaceutical drug research, specifically, in vitro cell culture is implemented 
in preclinical studies, relying on high-throughput screening (HTS) to rapidly access tens to 
hundreds of thousands of potential drug candidates for cytotoxic effects and their ability to 
modulate a biological target of interest.2 HTS is advantageous because it accelerates the preclinical 
drug development timeline and reduces costs associated with large sample volumes.2 However, 
HTS is often carried out in multi-well plates containing confluent 2D cell monolayers, thus lacking 
physiological fluid flow, 3D architecture, and complex cellular interactions.3,4 As a result, data 
acquired from 2D cell culture models may not reflect the results of in vivo studies or clinical trials 
due to differences in the biological response to a compound of interest. Nearly 95% of all 
compounds reaching clinical trials in the drug development pipeline ultimately fail, which costs 
pharmaceutical companies years of research and billions in USD.5 The high failure rate of drugs 
entering clinical trials can be attributed to a variety of factors such as irreproducibility, poor safety 
profiles, and differences in drug efficacy on cultured cells versus animals or humans.5  
To improve translation between in vitro models and clinical trials, Organ-on-a-Chip (OOC) 
technologies have emerged and quickly evolved over the last two decades. OOC devices integrate 
in vitro cell culture with microfluidic platforms to recapitulate complex organ-level physiology. 
While Schuler and colleagues were first to mimic organ-level physiology in a microfluidic device 
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in 2004,6 the term “Organ-on-a-Chip” was popularized by Donald Ingber in 2010 after developing 
the Lung-on-a-Chip,7 shown in Figure 1.1. The device consists of a cell-laden porous membrane 
placed between two polydimethylsiloxane (PDMS) layers containing microchannels and chambers 
for fluid flow and vacuum application, respectively. Epithelial and endothelial cells cover 
opposing sides of the porous membrane to represent the alveolus-capillary interface in the lungs. 
Chambers adjacent to the membrane deform upon cyclic vacuum application, mechanically 
stretching the porous membrane to simulate breathing-induced deformation of the alveolus-
capillary interface. Incorporating mechanical deformation into the model significantly altered the 
cells’ physiological response to various perturbations. As an example, the introduction of silica 
nanoparticles to the alveolar channel in conjunction with mechanical strain drastically upregulated 
expression of the transmembrane protein, ICAM-1, increasing neutrophil adhesion to endothelial 
cells.7 By providing physiological biomechanical cues, in vitro organ models more closely  
Figure 1.1 Schematic of the Lung-on-a-Chip illustrating the working principles and chip design. The chip 
simulates alveolus-capillary physiology by mimicking the air-liquid interface across epithelial and 
endothelial cell layers and providing cyclic strain. A) Vacuum suction provides cyclic strain to the epithelial 
monolayer. B) Mechanical strain induced on lung tissue in vivo when breathing. C) Layers of the Lung-on-
a-Chip. D) Fabrication of the side chambers. E) Images of an actual Lung-on-a-Chip device.  Reproduced 
from ref. 7 with permission from the The American Association for the Advancement of Science. 
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represent their in vivo counterparts.8 In addition to the lungs, organs such as the brain ,9 kidneys,10 
liver,11 heart,12 intestines,13 and many others have been modeled in microfluidic devices. Further, 
multiple organs have been combined in a single microfluidic platform to create Body-on-a-Chip 
devices capable of modeling systemic physiology.14,15   
 While most OOC devices rely on one or more cell lines to represent tissues and organs, 
several research groups have taken an alternative approach by utilizing tissue explants or precision 
cut tissue slices for ex vivo organ models.16-18 Compared to cell lines, both tissue explants and 
slices are advantageous because they retain the cellular diversity, three-dimensional architecture, 
and function of native tissues.19 However, integrating explants and slices into microfluidic devices 
presents challenges such as long-term tissue viability, inadequate nutrient diffusion through the 
tissue, and limited source availability.19 Thus, both approaches to modeling organ level physiology 
in OOC devices are necessary to bridge the gap between HTS and clinical trials. For OOC 
technologies to become widely adopted in the pharmaceutical industry as preclinical tools, 
protocols must be established outlining standard operating procedures and validation methods.20 
Additionally, factors such as cell/tissue variability, scalable manufacturing, and quantitative data 
extraction will influence OOC utility in the drug development pipeline.20  
 OOC technologies are a promising tool for translational research and disease modeling. 
Within a decade, OOC’s have evolved from one-off devices used exclusively in academic 
laboratories to commercialized products marketed to large pharmaceutical companies. While 2D 
cell monolayer cultures provide a necessary platform to rapidly screen many compounds in 
parallel, they fail to adequately predict a drug’s effect in vivo. OOC systems more faithfully 
recapitulate in vivo physiology, making them an attractive middle ground between traditional in 
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vitro cell culture and in vivo studies. As OOC technologies become more standardized in the 
pharmaceutical industry, there will likely be a paradigm shift in the drug development pipeline.  
1.2 The Intestine’s Role in Human Health and Disease 
 1.2.1 Anatomy and Physiology 
 The intestines primarily function as a selective barrier by absorbing nutrients and water, 
excreting waste, and defending against harmful substances and pathogens. Partially digested food 
(chyme) enters the small intestine where critical nutrients such as sugars, amino acids, and fatty 
acids are absorbed into the bloodstream. Remaining luminal content is then moved to the large 
intestine via peristalsis to be dehydrated and excreted. To function as a selective barrier, intestinal 
tissue is multilayered and composed of epithelial, neural, immune, muscular, and vascular 
components. Additionally, a thick mucus layer covers the intestinal epithelium, serving as a first 
line of defense against dangerous pathogens.  
As seen in Figure 1.2, the small intestine’s mucosal layer faces the lumen and contains 
three-dimensional finger-like structures (villi) lined by epithelial cells (e.g. enterocytes, goblet, 
Paneth), which increases surface area and improves nutrient absorption. Epithelial cells are 
connected to each other via tight junction proteins that prevent transcellular penetration of 
pathogens and other harmful substances. In diseased states, these tight junction proteins loosen, 
resulting in increased intestinal permeability. Intestinal glands, known as crypts, are located 
adjacent to the villi and contain several cell types, including stem cells. In humans, the intestinal 
epithelium is regenerated every 3-5 days as stem cells differentiate into epithelial cells and migrate 
apically up the crypt-villus axis.21 The mucosal layer also includes an extensive number of innate 
and adaptive immune cells within the lamina propria such as T cells, B cells, and dendritic cells. 
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Further, both vascular and neuronal components traverse all layers of the intestine and function 
synergistically with immune and epithelial cells to maintain homeostasis and regulate barrier 
function.22 As mentioned earlier, the intestines pass contents through the alimentary canal via 
segmental muscle contractions known as peristalsis. Within the intestinal muscle layer, two 
distinct muscle fiber orientations exist to enable peristaltic contractions: circular and longitudinal. 
Beneath the muscle layers, a lubricating serous membrane encapsulates the intestines to reduce 
friction against other organs. The intestine’s unique microenvironment, namely the presence of a 
steep oxygen gradient across the epithelial layer, distinguishes it from other barrier tissues. Oxygen 
tensions precipitously transition from 0.1-1 mmHg to 80-100 mmHg as one moves from the lumen 
to submucosa.24 Blood flow in the submucosal vasculature sufficiently oxygenates intestinal 
 
Figure 1.2 Cross sectional schematic illustrating the 4 main intestinal layers: Mucosa, Submucosa, Muscle, 
and Adventita/Serosa. The mucosal layer features a wide range of epithelial cells organized in 3D structures. 
Reproduced from ref. 23  
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tissue while lower oxygen concentrations maintain anaerobic bacterial populations in the lumen. 
The next section will further explore the relationship between host tissue, the intestinal 
microbiome, and human health and disease.  
 1.2.2 Host Tissue-Microbiome Interactions 
 The adult human gastrointestinal (GI) tract is home to trillions of bacteria spanning roughly 
~2000 individual species.25 Gut bacteria continuously communicate with each other and host tissue 
to modulate energy levels, immune responses, and barrier function among other physiological 
processes.26 For instance, bacteria metabolize undigested carbohydrates to produce the short chain 
fatty acids butyrate, propionate, and acetate, which act as signaling molecules to enhance tight 
junction formation between epithelial cells.27 The distribution and abundance of bacterial species 
in the intestine is dependent on a variety of genetic, dietary, and environmental factors.28 Research 
shows that changes in the gut microbiome, known as dysbiosis, are associated with a wide range 
of local and systemic diseases.29 Studies that investigate the relationship between dysbiosis and 
disease typically rely on 16S rRNA sequencing of bacteria from cell cultures or fecal samples.30 
Thus, there is debate on the degree to which dysbiosis regulates disease pathogenesis and vice 
versa. In some germ-free mouse studies, the prevalence or severity of certain autoimmune diseases 
(e.g. type 1 diabetes, autoimmune arthritis) was reduced under germ-free conditions.29 However, 
most studies have failed to link specific bacterial species to disease pathogenesis when isolated 
from the microbiome as a whole.29  
 One of the most common intestinal diseases is inflammatory bowel disease (IBD), 
classified as either ulcerative colitis (UC) or Crohn’s disease (CD). Both IBD subtypes are 
characterized by immune-mediated chronic inflammation of the intestine and are associated with 
unique microbial compositions.31 Studies analyzing biopsy or fecal bacterial profiles of IBD 
7 
 
patients have generally found increases in Enterobacteriaceae and decreases in microbial diversity, 
and some studies suggest these microbiome shifts precede or complement the onset of 
inflammation.31 As a complement to 16S rRNA sequencing, metabolic profiling of stool samples 
can elucidate some of the physiological mechanisms linking the gut microbiome to IBD. A recent 
study observed significant changes in metabolite abundance amongst UC and CD patients 
compared to controls, providing evidence that microbially-derived metabolites directly influence 
intestinal inflammation. As an example, IBD patients exhibited an overabundance of 
sphingolipids, a class of compounds present in both host cell and some bacterial cell membranes.32 
Sphingolipid equilibrium is vital for maintaining intestinal homeostasis, and dysregulation in the 
metabolism/production of certain sphingolipid molecules is associated with IBD pathogenesis.33 
Despite advances in metabolomics and metagenomics, however, established relationships between 
dysbiosis, metabolic changes, and IBD are correlative rather than causative.  
In addition to local diseases, research suggests the intestines play a significant role in the 
pathogenesis and progression of a variety of systemic diseases such as type 1 diabetes.34 Type 1 
diabetes is an autoimmune disorder characterized by T-cell mediated destruction of insulin-
producing pancreatic β-cells, resulting in elevated blood glucose levels. Genetic factors associated 
with type 1 diabetes are well established, and a host of environmental factors (e.g. viruses, diet) 
are also proposed to increase susceptibility to the disease.35 Considering the microbiome, several 
studies have observed increased Bacteroidetes/Firmicutes ratios, decreases in butyrate-producing 
bacteria, and decreased microbial diversity in type 1 diabetics.36-38 More recently, research 
suggests that gut bacteria are associated with type 1 diabetes pathogenesis via altered intestinal 
permeability and interactions with the innate and adaptive immune systems.39  Illustrated in Figure 
1.3, dysbiosis can increase intestinal permeability, allowing microbially-derived products to 
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infiltrate host tissue unregulated.40  In some cases, these products interact with enteric immune 
cells in a cascade of events ultimately leading to CD8+ T-cell activation and pancreatic β-cell 
destruction.40 While these findings appear to confirm causal relationships between gut bacteria and 
type 1 diabetes, more large-scale human studies are needed to draw definitive conclusions.  
 The enteric nervous system (ENS) is intrinsic to the intestines and regulates key enteric 
functions such as motility, local blood flow, absorption/secretion, and immune responses.41 As the 
body’s “second brain”, the ENS continuously and bi-directionally communicates with the central 
nervous system (CNS) along the gut-brain axis via spinal afferents and the vagus nerve.42  Research 
has associated dysbiosis with neurological and mood disorders ranging from Alzheimer’s disease 
to major depressive disorder,42,29 and the ENS provides a pathway for microbiome-brain 
Figure 1.3 Proposed mechanisms by which intestinal bacteria contribute to the pathogenesis of Type 1 
diabetes. Acronyms: MyD88 and TRIF are adaptor proteins; NOD2 is an intracellular pattern recognition 
receptor; APC is an antigen presenting cell; Th1, Th2, Th17 are T helper cells; Treg is a regulatory T cell; 
MAIT is a mucosal associated invariant T cell; iNKT are invariant natural killer T cells. Reproduced from 
ref. 40.   
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communication. More specifically, intestinal bacteria modulate the release of neuropeptides and 
other signaling molecules from enteric neurons and enteroendocrine cells, which in turn stimulates 
vagal and spinal afferent neurons leading to the brain.43 Here, it should be noted that the ENS is 
only one component of the gut-brain axis and that certain signaling molecules produced by either 
bacteria or host cells can impact brain physiology directly via systemic circulation or by 
stimulating enteric immune cells.43 Intestinal bacteria also produce and respond to several 
neurotransmitters  known to impact mood, including gamma-amino butyrate (GABA), serotonin, 
dopamine, and norepinephrine.44 Thus, dysbiosis alters the local availability of neurotransmitters 
and other neuroactive molecules absorbed by the intestines, ultimately impacting gut-brain 
communication.44 However, neurotransmitters produced in the intestines may not reach the brain 
directly, and their modulation of the gut-brain axis is not well understood.26 
 As evidenced in this section, the gut microbiome is associated with a growing number of 
local and systemic diseases through interactions with host tissue. 16S rRNA sequencing is a 
powerful method to identify and correlate microbial signatures with specific diseases, but a deeper 
understanding of the metabolites and pathways regulating host tissue-microbiome interactions is 
paramount for establishing causal relationships between dysbiosis and diseases. Though 
controversial, bacteriotherapy (i.e. fecal microbiota transplantation, probiotics) could become a 
viable treatment option for certain diseases in the future.29  However, research must first elucidate 
what comprises a “healthy gut microbiome”, and it is likely that genetic/environmental factors will 
vary the therapy’s efficacy between individuals.29  
1.3 Devices for Modeling Intestinal Physiology  
 1.3.1 The Ussing Chamber 
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 Since research has highlighted the critical role the intestines play in regulating human 
health, engineers and scientists have labored to design novel devices which enable recapitulation 
and analysis of intestinal physiology. The Ussing chamber, which was invented by Hans Ussing 
in the 1950’s to study ion transport across frog skin, is a device widely-used to measure intestinal 
permeability and barrier function.45 The classic Ussing chamber design, illustrated in Figure 1.4, 
consists of two buffer-filled acrylic half chambers separated by either intestinal mucosa or cultured 
epithelial cells. The buffer solution in each half chamber is maintained at a physiologic temperature 
and continuously gassed to 1) control dissolved O2/CO2 concentrations, and 2) stir the buffer for 
sufficient mixing. Further, most commercial systems are equipped with voltage-clamp/current-
clamp setups which enable transepithelial electrical measurements such as resistance (Rte), voltage 
(Vte), and short-circuit current (Isc).46 In voltage-clamp experiments, “voltage electrodes” 
connected to each half chamber via salt bridges record Vte while “current-passing electrodes” in 
each half chamber pass current across the tissue. A feedback loop is used to automatically adjust 




the applied current until the measured Vte matches a user-defined value (often 0V). Since Vte is 
constant, changes in the applied current are equal in magnitude and opposite in direction to ion 
transport through the tissue. The applied current is defined as Isc when Vte= 0V. Compared to 
voltage-clamping, current-clamping involves injecting a constant current through the tissue and 
measuring fluctuations in Vte. Both techniques enable transepithelial electrical resistance (TEER) 
to be calculated from Ohm’s law:  
                                                         𝑅𝑡𝑒 =  ∆𝑉∆𝐼                                                                   (1) 
TEER, which will be further discussed in a later section, is a standard measure of tissue 
permeability and health.47 Intestinal permeability to specific compounds can also be quantified in 
the Ussing chamber using bound radioactive or fluorescent probes.48 Both half-chambers are 
sampled periodically after adding the labeled test compound, and intestinal permeability is 
calculated from the following equation: 
                                                     𝑃𝑎𝑝𝑝 =  𝑑𝑄/𝑑𝑡𝑆𝐴∗𝐶0                                                                                (2) 
Here, dQ/dt is the linear rate of transport between chambers, SA is the tissue’s surface area, and 
C0 is the initial concentration of the drug in the apical chamber.  
 The Ussing chamber offers several advantages compared to Transwell models of the 
intestinal barrier, including compatibility with explanted tissue, integrated instrumentation for 
electrophysiological measurements, and convection near the tissue’s surfaces. While Ussing 
chamber studies have deepened our understanding of intestinal barrier function, many biological 
phenomena occur on timescales which exceed the device’s capabilities. Ussing chambers are 
unsuited for long term microbiome studies and diseases models since tissue viability is limited to 
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3 hours.48 The tissue’s rapid degeneration likely stems from 1) physical damage induced when 
mounting the tissue between half chambers, and 2) exposure to buffer solutions lacking critical 
nutrients. The standard protocol for mounting tissue involves radially stretching the intestinal 
mucosa across the chamber’s aperture, fastening the tissue’s periphery to one half chamber via 
metal pins, and clamping both half-chambers together to prevent leakage.48 While few studies have 
explored the effect of edge damage on bulk tissue health, one study showed that mounted ileal 
tissue segments exhibited altered villus morphology, cellular debris accumulation on the mucosal 
surface, and reduced mucosal thickness in regions adjacent to the chamber’s edge.49 Of concern, 
the authors noted that edge damage resulted in the inability to detect changes in transepithelial 
transport following exposure to hyperosmolar sodium chloride.49  
Modern commercial Ussing chambers are multiplexed and modular to increase throughput, 
improve usability, and reduce preparation time.45,48 Additionally, researchers have modified the 
classic chamber design to enable continuous perfusion or vacuum-assisted mounting of tissue 
segments,46,50 but no studies have directly investigated how various designs influence experiential 
results. The Ussing chamber remains the gold standard for studying transepithelial ion transport, 
and despite its limitations, has proven to be a valuable device for assessing intestinal barrier 
function ex vivo.  
1.3.2 Gut-on-a-Chip 
 Gut-on-a-Chip is an OOC technology adapted to model intestinal epithelium in vitro. One 
of the earliest Gut-on-a-Chip designs,13 developed by Harvard University’s Wyss Institute, is 
nearly identical to the Lung-on-a-Chip design7 and utilizes Caco-2 cells to represent the gut 
epithelium. Caco-2 cells are an established immortalized cell line for modeling intestinal 
permeability in vitro, but some of their functional characteristics differ from intestinal epithelial 
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cells in vivo.51 Further, while individual Caco-2 cells are morphologically similar to intestinal 
enterocytes,51 Caco-2 monolayers fail to capture the three-dimensional architecture and cellular 
diversity of the intestinal epithelium. However, Caco-2 monolayers cultured in the Gut-on-a-Chip 
developed villus-like structures in the presence of physiologic shear stress and mechanical strain, 
highlighting the impact of mechanical cues on tissue morphology.13 The physiological relevance 
of subsequent device iterations improved when Caco-2 monolayers were replaced with human 
small intestine-derived enteroids (intestinal organoids).52 The transcriptome of chips containing 
enteroids more closely matched that of human duodenum compared to chips containing Caco-2 
cells.52 The most recent Gut-on-a-Chip design enables the establishment of transepithelial oxygen 
gradients between microfluidic channels and the coculture of  host cells with intestinal anaerobic 
bacteria.53 In this design, however, the epithelium is represented by Caco-2 cells instead of human-
derived enteroids. In addition to the Gut-on-a-Chip, there are many other microfluidic intestinal 
models ranging in biological complexity. Table 1.1 compares the devices’ design characteristics. 
Excluding ex vivo models, all microfluidic devices listed in Table 1.1 lack immune, nervous, and 
muscular components of the gut wall. To date, no microfluidic intestinal model completely 
captures the interaction between host tissue and the microbiome in a physiological environment.  
 As briefly discussed in section 1.1, several research groups have modeled organ physiology 
ex vivo by integrating tissue slices or explant into microfluidic systems. However, intestinal tissue 
is particularly difficult to culture in microfluidic devices because the tissue must form a barrier 
between opposing compartments, yet muscular contractions cause the tissue’s periphery to curl 
towards its center axis. To the author’s knowledge, only one research group has reported a 
microfluidic device for the culture of full-thickness intestinal explants.56 Dawson et. al maintained 
full-thickness human intestinal explants (patients with IBD) for 72 h in a dual channel microfluidic 
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device providing continuous media perfusion. Explants were housed in a center PDMS chamber 
and petroleum jelly was applied around the tissue’s periphery to prevent media from crossing 
channels. Tissue was considered viable after 72 h of culture by assessing tissue architecture (H&E 
stain) and quantifying lactate dehydrogenase release and cell proliferation (Ki-67 stain). However, 
we challenge the authors’ claim that tissue was viable after 72 h because H&E stains of the explants 
at 72 h versus 0 h were markedly different. While use of intestinal explants better reflects host 
tissue dynamics, antibiotics added to the culture media precluded studies of host tissue-
microbiome interactions.  
In conclusion, microfluidic devices can be used to model intestinal physiology both  in vitro 
and ex vivo. Unlike static systems, microfluidic devices enable constant nutrient delivery  and 
waste removal from cells and tissues.19 In vitro systems like the Gut-on-a-Chip are valuable for 
higher throughput studies and reflect the dynamics of native intestinal tissue to some degree, but 
they lack necessary aspects of the gut wall. Ex vivo microfluidic intestinal models capture the 
cellular diversity and three-dimensional architecture of native tissue, but limited tissue viability 
and availability have prevented their wide-spread use. Ideally, the next generation of microfluidic 
Table 1.1 Comparison of various static and microfluidic models of the intestines. Adapted from ref. 54. 
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intestinal models will contain all components of the gut wall and enable researchers to study host 
tissue-microbiome interactions in relation to human health and disease. 
1.4 Design Considerations for an Ex Vivo Intestinal Model 
 1.4.1 Material and Manufacturing 
PDMS is an elastomeric polymer widely used to fabricate microfluidic chips and OOC 
devices since it is relatively inexpensive, easy to fabricate, optically transparent, and bonds to an 
array of substrates.19 Despite these advantages, certain PDMS material properties are problematic 
when designing a microfluidic device to model the intestines. Physiologically relevant intestinal 
models require a near-anoxic environment near the tissue’s mucosal surface, but PDMS’s high 
oxygen permeability allows oxygen to readily diffuse from the surrounding environment into 
culture media.56 In fact, Shin et al. accounted for oxygen flux through PDMS to accurately model 
oxygen transport in a microfluidic device lined with intestinal epithelial cells. Another drawback 
to PDMS is that it absorbs small hydrophobic molecules like pharmaceutical drugs.57 When 
utilizing microfluidic devices for drug metabolism studies or bioassays, PDMS absorption of small 
molecules dilutes media drug concentrations and skews study results.57 PDMS is not as ubiquitous 
in the OOC industry as it is in academic laboratories Industrial OOC devices are typically 
fabricated from various thermoplastics such as polycarbonate, polystyrene, and 
polymethylmethacrylate.58 Figure 1.5 compares materials commonly used to fabricate 
microfluidic devices and ranks their suitability for specific applications. Of the materials listed for 
tissue culture applications, cyclic olefin copolymer (COC) is well suited for ex vivo intestinal 
models because of its low oxygen permeability, minimal absorption of hydrophobic compounds, 
optical transparency, and biocompatibility.59,60 COC microfluidic chips can be fabricated via 
scalable manufacturing methods such as milling or injection-molding, which is critical for testing 
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multiple disposable microfluidic devices in parallel. By contrast, PDMS microfluidic devices are 
difficult to produce in mass quantities because fabrication requires manual labor and long curing 
times. While both milling and injection molding are viable manufacturing methods for plastic 
microfluidic devices, injection molding is more cost-effective as production volume increases 
despite high start-up costs.61 Additionally, the low shrinkage associated with injection molded 
COC provides engineers with more design flexibility. In conclusion, optimizing the design of an 
ex vivo intestinal model requires careful attention to material selection and manufacturing 
methods. COC is biocompatible and allows for low oxygen concentrations to be established on 
chip while injection-molding enables high volume production of parts at low costs long-term.  
1.4.2 On-Chip Microenvironment  
The in vivo intestinal environment features dynamic physical and chemical characteristics 
which regulate homeostasis. Ex vivo intestinal models should capture this environment to maintain 
Figure 1.5 comparison of materials used to fabricate microfluidic devices for various applications. 
Acronyms: Polydimethylsiloxane (PDMS); Polystyrene (PS); Cyclic Olefin Copolymer (COC). 
Reproduced from ref. 19 with permission from the Royal Society of Chemistry.  
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viable tissue and demonstrate physiological relevance. One defining characteristic of the intestines 
is the presence of a steep oxygen gradient from the lumen to the serosa, which is necessary for the 
survival of both anerobic bacteria and host tissue.24 In vivo, this gradient is maintained by a 
combination of bacterial and tissue oxygen consumption, convective oxygen transport through 
vasculature, and diffusive oxygen transport from blood to surrounding tissues.62 Mathematically, 
this process is governed by the convection-diffusion equation as follows: 
                             
𝜕𝑐𝜕𝑡 =  ∇ ∙ (𝐷∇𝑐) − ∇ ∙ (𝒗𝑐) + 𝑅                                                             (3)    
where c is species concentration, D is the diffusion coefficient, v is the velocity field of fluid 
carrying the species, and R is a reaction term accounting for species consumption or production. 
The del symbol ∇ acts as either the gradient operator (𝑖. 𝑒.  ∇𝑐) or divergence operator (i.e. ∇ ∙(𝒗𝑐)). At steady state (c/t = 0), tissue oxygen consumption is equal to the combination of 
convective and diffusive oxygen transport. Since intestinal tissue lacks blood supply ex vivo, the 
concentration of oxygen within explants depends on boundary conditions at the mucosal and 
serosal surfaces. In microfluidic devices, tissue oxygenation is enhanced by establishing a larger 
concentration difference between channels and increasing flow rates. Experimentally measuring 
tissue oxygen levels while varying model parameters is challenging and time-consuming. 
However, computational modeling allows engineers to efficiently optimize model parameters such 
that oxygen distribution within intestinal explants is comparable to native tissue.  
 When optimizing perfusion flow rates for intestinal explants cultured in microfluidic 
devices, one must consider the magnitude of applied shear stress in addition to oxygen transport. 
In the context of fluid mechanics, shear stress is the component of stress acting parallel to a surface 
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in contact with moving fluid. For Newtonian fluids, shear stress () is proportional to the shear rate 
(u/y) as shown in equation 4: 
                                                           𝜏 =  𝜇 𝜕𝑢𝜕𝑦                                                                    (4)        
 where μ is the dynamic viscosity, u is fluid velocity, and y is the distance from fluid-wall interface.   
Shear stress serves an important role in many tissues and has been shown to modulate cell 
morphology and function in the intestines.63 In vivo, the intestinal epithelium is subjected to low 
shear stresses ranging from .002-.08 dyne/cm2 due to the movement of chyme along the GI tract.13 
In microfluidic systems, the luminal flow rate should be adjusted to reflect physiologic shear stress 
values. Optimizing flow rates in the serosal channel is challenging because the intestinal serosa is 
not directly subjected to fluid flow in vivo. Rather, blood enters the serosa through mesentery 
arteries that are absent in ex vivo intestinal models.64 Therefore, serosal flow rates should be 
optimized by 1) maximizing oxygen delivery to the tissue and 2) experimentally quantifying tissue 
health as a function of shear stress acting on the serosa.  
 While not extensively discussed in this section, the physiological relevance of an ex vivo 
intestinal model depends on other environmental parameters such as temperature, pH, and media 
composition. Ultimately, the on-chip microenvironment must recapitulate in vivo conditions for 
tissue and bacteria to survive long-term ex vivo.   
 1.4.3 Quantification of Tissue Health and Barrier Integrity 
 In organotypic slice cultures, tissue health is typically quantified using histological stains, 
immunohistochemistry, and cell-based assays.65 Despite their utility, many of these techniques are 
implemented at the conclusion of experiments and do not provide real-time tissue health 
information. Barrier tissues such as the intestines are well-suited for non-invasive tissue health 
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analysis methods which include transepithelial electrical resistance (TEER) and  quantifying 
paracellular flux of fluorescently labeled compounds. In addition to being non-invasive, these 
methods allow for real-time monitoring of barrier integrity.  
 TEER is a widely accepted, reliable measure of epithelial barrier integrity in vitro.47 To 
obtain TEER values, electrodes are placed in opposing media filled compartments separated by an 
epithelial cell monolayer and a DC or AC voltage is applied. The measured current is converted to 
resistance or impedance values using Ohms law or equation 5, respectively. 
                                               𝑍 = 𝑉(𝑡)𝐼(𝑡) = 𝑉0 𝑠𝑖𝑛 𝜃𝐼0 𝑠𝑖𝑛 (2𝜋𝑓𝑡+∅)                                             (5) 
Here, V0 and I0 are the peak voltage and current,  is the phase shift, and f is the signal frequency. 
Resistance and impedance values reflect the integrity of tight junctions between cells, and TEER 
decreases as the epithelial barrier deteriorates. Impedance spectroscopy offers several advantages 
over traditional single frequency DC TEER measurements. Impedance values can be gathered over 
a wide range of frequencies, providing additional information such as cellular capacitance and 
membrane resistance.47 Additionally, unlike DC currents, AC currents do not cause adverse effects 
on cells.66 Figure 1.6 illustrates an equivalent circuit model for impedance measurements across 
an epithelial cell monolayer. In most systems, frequencies less than 100 Hz reflect TEER, 100 Hz-
10 kHz reflects cell capacitance, and frequencies greater than 10 kHz reflect media resistance.67 
While TEER circuit models are well defined for cell monolayers, circuit models for tissue explants 
are less understood because of additional layers underlying the epithelium. When considering 
intestinal tissue specifically, one potential concern is that electrical resistance contributions from 
the submucosal and muscular layers may dominate the resistance contribution from the epithelial 
layer. Some studies have measured TEER across full-thickness explants, but the contributions of 
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each tissue layer to the total electrical resistance was not discussed. Detailed TEER circuit models 
for multilayered tissues are needed to correlate TEER fluctuations to tight junction dynamics. 
Whether TEER measurements are valid for multilayered tissues depends on future development 
and testing of TEER sensors in ex vivo systems.        
  In addition to TEER, barrier integrity and tissue health can be quantified by monitoring the 
passage of fluorescently labeled compounds through tissues. This method yields specific 
information about paracellular spacing when using tracer compounds with defined molecular 
weights such as dextran (3-2000 kDa), mannitol (182 Da), and albumin (67 kDa) (Arik 2018). In 
static systems or Ussing chambers, media samples from each well or half chamber are taken 
periodically and assessed with a plate reader.48,68 The measured fluorescence intensity of each 
sample indicates the concentration of labeled compound.  Optically transparent OOC devices, 
Figure 1.6 (a) and (b) show the equivalent circuit model for impedance measurements across epithelial cell 
monolayers. (c) correlates individual circuit elements to specific frequency ranges. Acronyms: RTEER is 
transepithelial electrical resistance; RMedium is medium resistance; RMembrane is membrane resistance; CC is 
cell capacitance; CE is electrode capacitance. Reproduced from ref. 47. 
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when coupled with fluorescent microscopy, allow for real-time monitoring of compound 
concentration in the effluent media. For example, Adriani et. al. developed an OOC model of the 
blood-brain barrier and quantified endothelial permeability to labeled dextran by taking fluorescent 
images every minute.69 When measuring paracellular flux in microfluidic devices, both the input 
compound concentration and media flow rates should be optimized so that the effluent media is 
concentrated enough to detect changes in flux over time.68  
 Both TEER and paracellular flux measurements should be validated by traditional 
measures of tissue health and barrier integrity including tight junction protein expression and 
live/dead cell assays. Validation is crucial because TEER and paracellular flux measurements not 
only depend on tissue health/barrier integrity, but also device design, experimental setup, and 
tissue type. Overall, a well-designed ex vivo intestinal model should include methods for 
quantifying tissue health and barrier integrity in real-time to ensure that experimental results are 
physiologically relevant. 
 1.4.4  Real-Time Sensing of Analytes and Metabolites  
  On-chip sensors are increasingly becoming a standard feature of OOC devices due to 
advances in sensor development and chip fabrication.70 Unlike off-chip assays, online sensing 
enables real-time monitoring of physical and biochemical parameters, which is crucial to 
understanding how tissues respond to environmental perturbations.71 On-chip sensors typically 
rely on electrochemical or optical sensing motifs, both of which have distinct advantages and 
limitations depending on the analyte being detected.  
Electrochemical sensors are usually integrated into OOC devices by depositing and 
patterning metal electrodes on surfaces in contact with the microfluidic channels,70 although other 
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electrode fabrication methods exist such as inkjet printing.72 Electrochemical sensors rely on redox 
reactions at the electrode’s surface and the resulting signal is detected via potentiometric or 
amperometric methods.71 Enzymes are commonly incorporated into electrochemical sensors to 
increase selectivity for specific molecules like glucose, though poor enzyme stability can reduce 
the sensor’s accuracy over time.73 Further, electrochemical detection of amino acids, proteins, 
drugs, and many small molecules can be achieved by immobilizing antibodies or aptamers on the 
electrode’s surface.74 Electrochemical sensors are well-suited for OOC applications because they 
are easily fabricated, highly sensitive and selective, and relatively low cost.71 A recurrent challenge 
to electrochemically detecting analytes in complex culture medias is biofouling, whereby a fouling 
agent is passivated on the electrode surface.75 However, biofouling can be reduced by applying 
electrode coatings or surface modifications.75  
In addition to electrochemical sensors, optical sensors can be readily integrated into OOC 
systems because of the high optical transparency of microfluidic devices. While many optical 
sensing motifs exist, this section will discuss optical sensors that rely on fluorescence intensity and 
lifetime measurements. For these types of optical sensors, polymeric thin films are doped with an 
analyte specific fluorescent dye and attached to either the inner surface of a microfluidic channel 
or to the tip of a fiber optic probe.71 For the first scenario, the polymeric thin film is interrogated 
remotely and non-invasively using the fiber optic probe. For the second scenario, the fiber optic 
probe must be in direct contact with culture media so that the attached thin film is exposed to the 
analyte of interest. In both cases, fluorescence quenching is directly related to the analyte 
concentration via the Stern-Volmer relationship (Chapter 2, equation 1). Although optical sensing 
methods are non-invasive and avoid analyte consumption, they are susceptible to photobleaching 
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and small changes in fiber optic probe positioning relative to the polymer film can significantly 
alter measurements.71    
When considering the design of an ex vivo intestinal model, a microfluidic platform should 
accommodate both optical and electrochemical sensors in some capacity to maximize the range of 
detectable analytes and metabolites. However, the compact size of microfluidic devices limits the 
number of sensors that can be integrated into a single chip. One solution is to integrate additional 
sensors into microfluidic devices in line with the device housing tissue. Indeed, on-chip sensors 
could be reserved for monitoring the intestinal microenvironment (i.e. oxygen, pH) while 
downstream sensors could be used to detect analytes associated with tissue and microbial 
metabolism (i.e. glucose, lactate). Since the intestines are comprised of epithelial, neural, immune, 
muscular, vascular, and microbial components, there are a multitude of analytes relevant to 
intestinal physiology, many of which are summarized in Table 1.2. Sensing each of these analytes 
in real-time from one tissue sample is a formidable endeavor. However, by collecting effluent 
media in fractions over time, many of these analytes could be measured at the conclusion of 
experiments via mass spectrometry or other analytical techniques. Additionally, multiplexing 
tissue chips would allow experimenters to sense various analytes from different tissue samples. 
Ultimately, the type and number of sensors used in any given experiment will depend on the 
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CHAPTER 2. A MICROFLUIDIC ORGANOTYPIC DEVICE FOR CULTURE OF 
MAMALLIAN INTESTINE EX VIVO 
2.1 Summary 
The physiological characteristics of the gastrointestinal (GI) tract are diverse and include 
rapid rates of epithelial turnover, complex nervous and immune systems, a thick mucus layer, and 
a large microbial population. Most GI models in vitro rely upon cell lines or organoids and 
consequently lack the diversity of cells and microorganisms present in vivo. In vivo studies retain 
function and cellular diversity but are more difficult to control. Microfluidic tissue-on-a-chip 
devices provide powerful alternatives for modeling physiological systems. Such devices show 
promise for use in GI research; however, most models use non-physiologic culture environments 
with higher than in vivo oxygen levels and insufficient gut microbiota. Our goal is to create a 
bridge between in vitro and in vivo using microfluidic devices by incorporating ex vivo tissue 
explants in physiologically relevant environments. Here, we report a microfluidic organotypic 
device (MOD) that enables media flow with differential oxygen concentrations across luminal and 
muscular surfaces of gut tissue ex vivo. Tissue was shown to be viable for 72 h and lowering 
oxygen concentration to a more physiologic level impacted bacterial populations. 
2.2 Introduction 
Intestinal tissue is composed of a complex network of epithelial, neural, immune, muscular, 
and vascular components.1 Bacteria that inhabit the intestinal lumen are major contributors to 
maintaining intestinal homeostasis. An imbalance in microbial communities (dysbiosis) is 
associated with a variety of local tissue diseases such as inflammatory bowel (IBD) and celiac 
disease.2,3 More globally, dysbiosis influences disorders ranging from cardiovascular disease to 
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brain function.4,5  For in vitro and ex vivo intestinal models, cellular diversity and recapitulation 
of the in vivo environment is paramount to better understanding the relationship between dysbiosis 
and disease. For instance, bacterial cell products can activate intestinal neurons, leading to the 
release of inflammatory cytokines associated with IBD.6 Traditional in vitro cell culture can 
recapitulate some aspects of intestinal physiology and is useful for high throughput screening, but 
these models often rely upon cell monolayers to represent the intestinal barrier. Cell monolayers 
lack the in vivo cellular diversity from both a mammalian host and bacterial perspective and do 
not accurately represent the three-dimensional architecture of the intestinal wall.7,8 Three-
dimensional intestinal organoids overcome some of these limitations by integrating multiple 
epithelial cell subtypes and exhibiting villus/crypt organization, but they are generally missing the 
neural, immune, and muscular components of the gut wall.8,9  
Improving upon static transwell models, ‘gut-on-a-chip’ microfluidic devices have been 
developed that allow media to be continuously perfused across opposing sides of a cell-seeded 
porous membrane representing the intestinal epithelial barrier.10-13  The incorporation of 
microfluidics in these devices improves cellular viability and longevity, constantly removes toxic 
cellular waste, and allows for controlled nutrient delivery.14 Recently, microbes have been 
incorporated into some in vitro microfluidic intestinal models by generating an oxygen gradient 
between microfluidic channels.15-19  
Organotypic intestinal culture models are an attractive middle ground between in vitro and 
in vivo systems because they include the three-dimensional architecture of the gut wall while still 
providing easily controllable experimental parameters.20 Ex vivo models of various tissues have 
been successfully used in microfluidic devices previously.21-25 Ex vivo models, however, are 
generally low-throughput compared to cell-monolayer cultures and many have limited long-term 
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tissue viability.8,26 The Ussing chamber is a well-established ex vivo model for studying trans-
epithelial drug, nutrient, and ion transport. While the Ussing chamber is valuable for 
pharmacokinetic/pharmacodynamic studies, viable epithelial tissue can only be maintained for 
several hours,27,28 making these models inappropriate for long-term host tissue-microbiome 
interaction studies.29 In this report, we describe the design and testing of a microfluidic organotypic 
device (MOD) for use with mammalian intestinal explants ex vivo. The MOD houses full-thickness 
mouse intestinal tissue, including muscular, neural, immune, and epithelial components. The MOD 
system was used to maintain mouse intestinal explants for 72 h, with differential bacterial growth 
as a function of oxygen concentration.  
2.3 Methods  
Device prototypes were designed in SolidWorks (Dassault Systemes, Waltham, MA) and 
3D printed with a Form 2 SLA printer (Formlabs, Somerville, MA). Once a final device design 
was established, the MOD was manufactured via injection molding (Applied Medical, Rancho 
Santa Margarita, CA) using cyclic olefin copolymer (COC; TOPAS Grade 8007) as material. All 
devices used during tissue testing were injection molded. Injection molding was chosen over other 
microfluidic device manufacturing methods because of its reproducibility and potential for large-
scale manufacturing.30 COC was chosen because of its biocompatibility, high chemical resistance, 
low oxygen permeability, and excellent optical properties.31-33 
The MOD (Figure 2.1) consists of three COC layers separated by polyurethane gaskets 
(PORON® AquaPro™, Rogers Corporation, Chandler, AZ); the gaskets define independent 
fluidic channels (10 mm wide, 1.1 mm deep, ~ 50 mm long, ~ 450 μL). Intestinal tissue is housed 
in the middle layer such that the mucosa and serosa face independent channels. The edge of the 
tissue is supported by a thin lip molded into the middle layer, eliminating the need for a porous 
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membrane. The top layer was designed with integrated snap-fit fasteners for rapid, reversible 
assembly (Video S1), which is crucial to minimizing the time tissue explants are without media. 
Unlike other fasteners, snap-fit fasteners can be injection molded and enable consistent assembly 
regardless of the user. Both the top and bottom layers contain threaded inlet and outlet ports that 
connect to 10-32 PEEK finger-tight fittings (IDEX Health & Science, LLC, Oak Harbor, WA). 
Rubber O-rings were installed at the base of each port to ensure airtight leakproof connections 
(IDEX Health & Science, LLC, Oak Harbor, WA). Glass coverslips (VWR, Radnor, PA) were 
fixed on the top and bottom layers using cyanoacrylate glue (Krazy Glue, Elmers Products, High 
Point, NC) directly above the tissue to enable on-chip imaging and tissue visualization (VWR, 
Radnor, PA). Quick setting epoxy was applied around the edges of the coverslips to further prevent  
Figure 2.1 Schematic illustration of the MOD design and maintenance of tissue explants 
ex vivo.  (A) an exploded model of the MOD system showing luminal (red) and serosal 
(blue) flow paths.  (B) image of mouse colon explant inside the MOD. (C) image of colon 
explant tissue at 0h ex vivo through the viewing window.  (D) image of different colon 
explant tissue at 72 h ex vivo through viewing window. Scale bars in C and D are 2 mm. 
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leakage and the top and bottom layers were placed in a 65° C oven for 15 min.  
As a first step in instrumenting the device, oxygen sensor spots (OptiEnz, Fort Collins, 
CO) were adhered to the inner surface of the top layer downstream of the tissue chamber. The 
sensor’s response was measured at two dissolved oxygen concentrations (DOC) using an external 
fiber optic probe (OptiEnz, Fort Collins, CO) to allow for the estimation of real-time DOC using 
the Stern-Volmer relationship:                                                                   
                    
𝜏0𝜏 = 1 + 𝐾𝑆𝑉[𝑂2]   ,                                                           (1) 
where τ0 is the luminescent decay time in the absence of oxygen, τ is the luminescent decay time 
in the presence of oxygen, KSV is the Stern-Volmer constant, and [O2] is the oxygen concentration. 
Fluorescence of an oxygen-sensitive compound on the sensor spot is quenched in the presence of 
oxygen, leading to a reduction in luminescent decay time.34 
After assembly, each device was tested for failure modes, sterilized, and placed in a sterile 
environment until use. All fittings, ferrules, and tubing were submerged in diluted (1:10) bleach 
for 10 min, rinsed thoroughly with DI water, placed in a soapy water bath and vigorously scrubbed.  
After a second DI water rinse, the components and devices were submerged in a 70% ethanol 
solution containing 0.1% benzalkonium chloride for 30 min and rinsed with sterile water. Lastly, 
all other components including the gaskets and collection tubes were autoclaved at 120°C for 25 
min. The devices could not be autoclaved due to COC’s glass transition temperature of 78°C. 
Culture media was composed of CTS Neurobasal-A Medium (Thermo Fisher Scientific, Waltham, 
MA), 5% (v/v) 1M HEPES Buffer (Sigma Aldrich, St. Louis, MO), 2% (v/v) B-27 Supplement 
(Thermo Fisher Scientific, Waltham, WA) and supplemented with 10 μM Nicardipine (Sigma 
Aldrich, St. Louis, MO), an L-type calcium ion channel blocker, that has previously been shown 
to block intestinal contractions ex vivo, a necessity when culturing intestinal tissue slices beyond 
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48 h.35  CTS Neurobasal-A Medium was chosen as its predecessor, neurobasal media, has proven 
reliable in maintaining healthy explant slices from both mouse35 and human36 intestines, among 
numerous other organs37, 38, 39. For each device, two syringes were filled with media (one 
containing 99.3 µM fluorescein), connected to NE-300 syringe pumps (New Era Pump Systems 
Inc., Farmingdale, NY) and equilibrated in a 37°C incubator prior to experiments to remove any 
air bubbles formed by the expansion of dissolved gasses in the media. Mouse tissue was prepared 
as previously described35 from mice approved under the Colorado State University IACUC 
protocol 17-720(A). Briefly, adult mice were sacrificed and the entirety of the large intestine was 
removed and placed in 4° C 1X Krebs buffer (in mM: 126 NaCl, 2.5 KCl, 2.5 CaCl2, 1.2 NaH2PO4, 
1.2 MgCl2). The cecum was removed and  the colon was cut longitudinally along the mesenteric 
border to open the lumen and form a flat sheet of tissue.  Only ascending, transverse, and 
descending colon were used for device experiments. Tissue was free-hand dissected to form slices 
with a diameter of ~5 mm and placed in the center of the middle device layer. Cyanoacrylate glue 
was applied around the perimeter of the tissue to fill gaps between the tissue and plastic. While 
cyanoacrylate glue has been reported to be cytotoxic,40 we only observed higher than expected 
levels of cell death where the glue directly contacted the tissue.  After securing the tissue in the 
middle device layer, the device was quickly assembled by stacking successive layers separated by 
the gaskets and snapping them together. The devices were placed in a 37° C incubator, connected 
to syringes, and purged with media at a flow rate of 2.5 mL/hr. Media containing fluorescein was 
perfused through the luminal channel while media without fluorescein was perfused through the 
serosal channel. Once effluent media reached the collection tubes, the flow rate was reduced to 
250 μL/hr for the remainder of the experiments to provide low shear stress across the tissue. 
Collection tubes were changed every 10 h and immediately stored at -80°C. Colon explants used 
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for mucus experiments were cultured for 48 h before the addition of an azido-modified 
galactosamine, Tetraacetylated N-Azidoacetylgalactosamine (GalNAz; 12.5 µM; Fisher 
Scientific, Pittsburgh, PA). At the conclusion of experiments, tissue explants were removed from 
the devices and placed in media containing either Ethidium Homodimer III (EtHD; Biotium, 
Hayward, CA) at a concentration of 2.5 µM to evaluate cell death, or a fluorophore-tagged alkyne, 
Dibenzocyclooctyne-Cy3 (DBCO-Cy3; 2 µM; Sigma-Aldrich, St. Louis, MO). After 30 min of 
incubation with EtHD, or 15 min of incubation with DBCO-Cy3, tissue explants were washed 
three times with culture media and fixed in 4% formaldehyde for a minimum of 8 h. Fixed tissue 
was washed with, and stored in, cold 0.05 M PBS until further analysis. A total of 27 devices were 
used for experiments, 4 of which were discarded due to breakage of the cyanoacrylate barrier 
separating the fluidic channels.  
Fixed explants were sectioned at 50 µm thick on a vibrating microtome (VT1000s, Leica 
Microsystems, Wetzlar, Germany) before mounting on glass microscope slides. Imaging was 
performed on a Nikon TE2000-U inverted microscope (20x Plan-Apo objective) with a UniBlitz 
shutter system (Vincent Associates, Rochester, NY) and an Orca-flash 4.0 LT camera 
(Hamamatsu, Hamamatsu City, Shizuoka Prefecture, Japan).  
 Fluorescein quantities contained in culture media effluents were analyzed using an Epoch 
Gen5 Microplate Spectrophotometer (BioTek, Winooski, VT) with a wavelength of 488 nm.  
Absorbance was quantified in effluent media from both channels in 10 h increments, with hour 0 
representing initial placement of explants into devices. Background signal from phenol red, a 




2.4 Results and Discussion 
Mouse colon explants were cultured in the MOD for up to 72 h ex vivo in both low and 
ambient mucosal DOC maintaining healthy, intact tissue (Supplemental Figure 1A-C). Tissue 
health was marked by maintenance of patterned rows of colonic crypts, with interspersed lamina 
propria and stereotypic arrangement of intestinal submucosal and muscular layers (Figure 2.2A, 
B, C). Minimal cell death was shown across 0h – 72h ex vivo (Figure 2.2D, E, F), indicated by 
labelling with EtHD. As expected, some EtHD was observed at the apical most epithelium, but not 
at the base of colonic crypts. Stem/progenitor cells at the base of colonic crypts proliferate and 
progeny migrate along the length of the crypt, towards the luminal aspect, before undergoing 
apoptosis and sloughing off into the intestinal lumen.41 This cycle is continuously repeated to 
regenerate a new epithelium every 2-3 days in the mouse.42 Minimal cell death observed 
throughout our explants during ex vivo culture, coupled with the EtHD signal at the apical most 
aspect of the crypt, points towards healthy tissue undergoing normal epithelial turnover. While 
others have maintained mammalian intestines in microfluidic devices for up to 72 h,43 evidence of 
tissue health was minimal. Another concern in many systems15, 43-45 is that serum-containing media 
with supplemented antibiotics was used to culture the tissue. A key advantage of the MOD is that 
we have maintained tissue in serum-free media, without antibiotics, which enables controlled 
substance delivery to the tissue as well as studying the role of bacteria on tissue health and 
physiology.  
In addition to maintaining viable tissue for 72 h, media was separated in independent 
microfluidic channels facing the mucosal and serosal sides of the tissue. Mean (+/- standard 
deviation) absorbance across all time points for luminal effluents was 0.11 +/- 0.03 and 0.00 +/-
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0.02 for serosal effluents, indicating that media did not cross channels throughout the duration of 
the experiments (Figure 2.3). One potential concern is that fluorescein leakage could be diluted by 
the fluid flow, under the spectrophotometer’s detection limit. Since fluorescein and fluorescein-
isothiocyanate are commonly used to assess barrier permeability in vivo46 and in vitro,47 any 
leakage below the detection limit is not biologically significant as an indication of barrier 
disruption. If media had crossed through the tissue, absorbance values would have increased 
substantially in the serosal effluent due to transfer or leakage of fluorescein across the tissue. 
Figure 2.2 Tissue health was maintained for 72 h ex vivo in the MOD in both ambient and low 
oxygen conditions. Brightfield images in A-C demonstrate patterned rows of colonic crypts, and 
stereotypic anatomical arrangement of gut wall musculature and submucosa at 0h (A), 72 h in 
ambient oxygen (B) and 72 h in low oxygen (C).  Fluorescent images in D-F demonstrate EtHD 
labelling in colonic explants, with stereotypic signal observed at apical most aspect of colonic 
crypts (arrows) at 0h (D), 72 h in ambient oxygen (E) and 72h in low oxygen (F).  ‘L’ denotes 
intestinal lumen, ‘m’ indicates mucosa, ‘sm’ submucosa, and ‘me’ muscularis externa.  Scale bars 
in A and B are 100 µm, scale bar in C is 50 µm, and scale bars in D-F are 25 µm. 
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Another potential concern is the reliability of the cyanoacrylate seal around the tissue. In ~15% of 
the devices tested, tissue lost adhesion to the cyanoacrylate glue and media was allowed to freely 
transfer between channels. Future iterations of the MOD will be designed to reduce device failure 
rates and increase experimental repeatability. The verification of media separation is a critical 
indicator that the gut wall tissue retained one of its most essential features ex vivo, that of a physical 
barrier with tight junctions between cells. This helps ensure that pathogens, pharmaceuticals, and 
other compounds of interest for study ex vivo can only access tissue physiology by going through 
normal cellular processes (e.g., active transport, diffusion, cellular transfer). By comparison, in 
most organ-on-a-chip devices, a barrier is formed by a confluent cell monolayer without the 
underlying cellular diversity needed to understand intestinal physiology.  
Figure 2.3 Media was separated across channels as marked by fluorescein absorbance in effluent 
media. Mean absorbance (A.U.) at 488 nm wavelength demonstrates significantly more 
fluorescein presence in mucosal (circular points) effluents compared to serosal (square points) (P 
< 0.001).  No significant differences were observed across time in either the mucosal (P > 0.20) or 
serosal (P > 0.45) effluents. All statistical analyses were performed using a one-way ANOVA with 
α = .05. Representative images show visible green color from fluorescein in mucosal (m) effluent 
compared to serosal (s) effluent.  
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The MOD enabled recapitulation of the in vivo oxygen gradient across the epithelial layer. 
DOC in the luminal channel were maintained at 3.0 +/- 0.38 mmHg for 48 h using 0.5 M sodium 
sulfite. In vivo intraluminal oxygen concentrations at the mucosal interface are nearly anoxic.48 
Perfusion of low oxygen-containing media within the luminal microfluidic channel increased 
bacterial presence on the tissue’s mucosal surface compared to tissue perfused with media at 
ambient oxygen levels (~ 100 mmHg), as marked by fluorescent gram stain35 (Figure 2.4A-F). 
Increases were most notable for gram-negative bacteria. Increased bacterial presence in a low 
oxygen environment was expected since many bacteria in the colon are anaerobic.49 Therefore, 
recapitulation of the in vivo oxygen gradient is vital to studying host tissue interactions with a more 
diverse, physiologically relevant bacterial community. It is also important to note that these 
experiments are proof-of-principle. Quantifying specific bacteria and overall bacteria 
concentrations will be the focus of future reports. 
Microfluidics provide a mechanism of tissue perfusion ex vivo that should allow for 
healthier tissue over longer periods.14 Previous ex vivo systems such as intestinal organotypic slices 
maintained tissue for 6 days, but without a true luminal barrier.35 Other methods such as Ussing 
chambers maintain full thickness tissues with an intact barrier, but with limited viability over a 
few hours.27  Using dual flow microfluidics, the MOD allows for the culture of full thickness 






Figure 2.4 Microbiota were maintained in the MOD, and more bacteria were visible in an explant 
cultured in lower oxygen conditions.  Baseline bacterial levels are shown at 0h ex vivo via 
hexidium iodide (7.05 µM) fluorescence in red (A), signifying Gram-positive bacteria, and SYTO9 
(5.01 µM) fluorescence in green (A’), signifying Gram-negative bacteria.  Gram stain fluorescence 
was noticeably higher in tissue cultured in lowered oxygen conditions (B-B’; 3 mmHg) when 
compared to tissue cultured in ambient oxygen (C-C’; 100 mmHg) containing media.  Arrows in 




In conclusion, a novel ex vivo microfluidic organotypic device was designed and tested. 
This system maintains viable polarized murine intestinal explants for 72 h ex vivo and enables a 
physiological oxygen gradient to be established between independent microfluidic channels 
rendering luminal and vascular compartments. The MOD bridges a substantial gap in current 
approaches to modeling barrier tissue as it overcomes several limitations associated with both in 
vitro and in vivo models. Due to the culture of full thickness explants, the MOD more closely 
recapitulates the in vivo physiology of the gut wall, as tissue explants include the complex 
cellular diversity and native tissue structural relationships of the gut wall. The MOD system 
offers a novel approach to culturing intestinal tissues with intact luminal barriers.  
Future extensions to the MOD will include developing and integrating optical and/or 
electrochemical sensors for analytes relevant to the intestinal environment (i.e. glucose, lactate). 
Electrodes can be added to assess transepithelial electrical resistance, which has been a useful 
measure of barrier integrity in other systems.15,50,51 Ultimately, the MOD will be implemented in 
long-term microbiome studies to elucidate the relationship among microbial, epithelial, neuro 
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CHAPTER 3: A MAGNETICALLY ASSEMBLED MICROFLUIDIC SENSOR MODULE 
FOR ORGAN-ON-A-CHIP SYSTEMS 
3.1 Introduction 
 As Organ-on-a-Chip (OOC) technologies continue to evolve, there is a growing need for 
integrated sensors that enable real-time monitoring of tissue-specific physiological processes. 
Traditional analytical methods heavily rely on sample collection and off-chip assays which lack 
sufficient temporal resolution and require large working volumes.1 Two classes of sensors, 
electrochemical and optical, are well suited for integration into OOC devices because they are 
highly sensitive and selective, cost-effective, can be readily fabricated at micro scales, and exhibit 
fast response times.2 Indeed, numerous OOC devices feature on-chip electrochemical or optical 
biosensors to monitor changes in environmental parameters (e.g. O2, pH, CO2),3-6 metabolic 
products (e.g. glucose, lactate),7,8 and cell-secreted molecules (e.g. cytokines)9,10 amongst other 
biomolecules. Due to limited on-chip space, a common approach is to integrate sensors into 
microfluidic platforms in-line with chips containing cells or tissues. Off-chip auxiliary sensor 
modules are particularly useful for multi-organ models and Body-on-a-Chip systems requiring 
simultaneous detection of many analytes in real-time. For example, Zhang et al. developed a 
liver/heart OOC platform with inline bioelectrochemical and physical/chemical sensing modules 
to monitor microenvironment parameters and measure soluble protein biomarkers in real-time. 
However, one drawback to this system and many others is that the sensors and microfluidic chips 
are irreversibly bound, requiring both components to be refabricated if either component fails. 
Alternatively, sensor modules designed with plug-and-play architectures are advantageous 
because individual sensors can be hot-swapped when failures occur, and microfluidic platforms 
can be reused in separate experiments requiring different sensors. Examples of plug-and-play 
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sensor modules include 3D-printed microfluidic devices that accommodate electrochemical 
sensors housed in PEEK finger-tight fittings11 or custom holders,12,13 as well as a 3D-printed flow 
cells that accommodate off-the-shelf optical components.14,15  
3D-printing is an attractive method for microfluidic device fabrication because it enables 
rapid prototyping of different designs in one step, and in some cases, multiple materials with 
different mechanical properties can be printed simultaneously.13,16 One disadvantage to 3D-
printing microfluidic devices is the need to remove uncured material from internal channels, which 
is challenging and time-consuming.17 Channel clogging can be circumvented by 3D-printing open-
faced microfluidic devices  and reversibly or irreversibly sealing the printed parts to various 
substrates.18-21 Reversibly sealed microfluidic devices are especially desirable for OOC 
applications because they can be disassembled, sterilized, and reused following experiments.22 
Different methods have been used to reversibly seal microfluidic devices, such as adhesive 
bonds,23,24 vacuum suction,25,26 and mechanical clamps fastened with screws27,28 or magnets.29-33   
Here, we report a novel plug-and-play sensor module for use in OOC systems. The 
microfluidic platform consists of two 3D-printed layers separated by either a silicone gasket or 
PDMS chip with defined microfluidic channels. Magnets installed in each 3D printed layer provide  
high-pressure reversible seals and allow for rapid assembly and disassembly. The top 3D-printed 
layer contains threaded ports that accommodate both electrochemical and optical sensors housed 
in commercial PEEK finger tight fittings. Importantly, this design reduces fabrication costs since  
both the microfluidic platform and sensors can be cleaned and reused between experiments. 
Additionally, the sensor module’s plug-and-play architecture enables it to be used for different 




3.2 Methods  
Device Design 
 Devices were designed in SolidWorks CAD software (Dassault Systemes, Waltham, MA) 
and the top and bottom layers were 3D-printed with a Form 3 SLA printer (Formlabs, Somerville, 
MA) using Clear V4 resin. After printing, the devices were soaked in isopropyl alcohol for 20 
minutes to remove uncured resin and subsequently post-cured according to Formlabs 
recommendations. All 3D-printed devices were coated with a silicone-modified conformal coating 
(MG Chemicals, Surrey, BC) to provide a smooth surface finish and improve optical transparency.  
N42 Neodymium bar magnets (K&J Magnets Inc., Pipersville, PA) were installed in slots on the 
inner surface of each 3D-printed layer using cyanoacrylate glue (Krazy Glue, Elmers Products, 
High Point, NC), providing ~11.5 lbf of total clamping force. Since the pull force between two 
magnets is reduced by a factor of 2 when separated by only 650 μm, the device was intentionally 
designed such that opposing magnets are nearly in contact after device assembly. Shown in Figure 
3.1, we designed two distinct microfluidic platforms with different middle layers to demonstrate  
the versatility of magnetic connections.  
In the first design (fig. 3.1A), the middle layer consists of a 20A durometer silicone gasket 
(McMaster-Carr, Elmhurst, IL) cut with an Epilog Zing laser cutter to define the microfluidic 
channel (1 mm width, 200 μm height, 33 mm length). To ensure a consistent channel height, the 
gasket was compressed by a set percent (25%) of its original thickness. The allowable percent 
compression was estimated by first converting the maximum clamping force provided by the 
magnets to a clamping pressure using the following equation: 
                                                   𝑃𝑐𝑙𝑎𝑚𝑝 =  𝐹𝑐𝑙𝑎𝑚𝑝𝑆𝐴𝑔𝑎𝑠𝑘𝑒𝑡                                                               (1) 
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Pclamp was subsequently compared to a compression-deflection curve for 20A durometer silicone 
gaskets, which defines the pressure needed to compress a material by a given percent. The top 3D-
printed layer contains threaded inlet/outlet ports and two sensor ports that are compatible with 10-
32 and ¼-28 finger-tight fittings (IDEX Health and Science, LLC, Oak Harbor, WA), respectively. 
The bottom 3D printed layer features notches aligned with the sensor ports which prevent installed 
sensors from occluding the microfluidic channel. Rubber O-rings were installed at the base of the 
inlet/outlet ports to ensure leak-free connections.  
In the second design (fig. 3.1b), the middle layer comprises a PDMS chip with an open-
faced microfluidic channel (500 μm width, 200 μm height, 33 mm length). The PDMS chip was 
fabricated using a 3D-printed mold combined with conventional soft lithographic techniques (Qin 
2010). Briefly, Sylgard 184 silicone elastomer base and Sylgard 184 elastomer curing agent were 
thoroughly mixed at a 10:1 ratio and degassed in a vacuum desiccator. The mixture was then cast 
Figure 3.1 CAD drawing of the magnetically assembled sensor module. A) In design 1, the microfluidic 
channel is defined by a laser cut  gasket. B) In design 2, the microfluidic channel is embedded in a PDMS 




over the 3D-printed mold and cured for 24 h in an 80°C oven. A 10:1 elastomer base to curing 
agent ratio was chosen because higher ratios (e.g. 15:1) resulted in significant channel deformation 
under compression. 18G steel connectors were inserted into biopsy-punched holes at the inlet and 
outlet to establish fluidic connections.  
Leakage Tests 
 We evaluated the sealing performance of each device design with two different magnet 
arrangements. Magnets were either installed along the devices’ sides parallel to the channel axis 
or around the devices’ periphery providing more equal spacing. Leakage tests were carried out as 
follows: 
1. A 60 mL syringe filled with colored DI water was loaded on an NE-300 syringe pump 
(New Era Pump Systems Inc., Farmingdale, NY) and connected to an assembled device 
using commercial fittings and tubing.  
2. An F-238 NanoTight Capilary sleeve (IDEX Health and Science, LLC, Oak Harbor, WA)  
was connected to the device’s outlet to provide additional fluidic resistance. 
3. Fluid was pumped through the device for 30 seconds in 0.5 mL/min increments until 
leakage was observed. This process was repeated for all devices and magnet arrangements. 
Volumetric flow rates (Q) were converted to pressure values (ΔP)  using the following equation: 
                                                        ∆𝑃 = 𝑄𝑅𝑡𝑜𝑡𝑎𝑙                                                           (2) 
Rtotal is the combined fluidic resistance provided by the microfluidic channel and capillary sleeve. 
The individual resistance contributions from the microfluidic channel and capilary sleeve were 
calculated from equations 3 and 4, respectively:  
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                                              𝑅𝑐ℎ𝑎𝑛𝑛𝑒𝑙 =  12𝜇𝐿𝑤ℎ3(1−0.63ℎ𝑤)                                                              (3)                                                                            
                                                     𝑅𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 = 8𝜇𝐿𝜋𝑟4                                          (4) 
Here, μ is the dynamic viscosity, L is the channel length, w is the channel width, h is the channel 
height, and r is the capillary inner diameter.        
Electrode Fabrication     
Electrochemical sensors were made by heat-pressing a previously reported thermoplastic 
electrode (TPE) material34 into ¼-28 PEEK finger-tight fittings. To fabricate the electrode 
material, polycaprolactone (PCL) pellets (ThermoMorph®) were first dissolved in 
dichloromethane followed by the addition of graphite (Grade 3569, Asbury Graphite Mills, INC., 
Asbury, NJ) at a 3:1 (w/w) graphite to PCL  ratio. Once homogenized, the mixture was poured 
onto a silicon wafer and the solvent was allowed to evaporate. The dried material was then molded 
into finger-tight fittings using a hydraulic heat press set to 75°C. Next, the ends of the finger-tight 
fittings were sanded and polished to remove contaminates, and the electrodes’ conductivity were 
measured for quality control purposes. Electrical connections were established using electrical 
wire and silver paint, and epoxy was applied over the connections for mechanical reinforcement. 
Prior to electrochemical experiments, finger-tight fittings were wrapped with Teflon tape to 
prevent leakage from the sensor ports.  
Electrochemical Experiments 
 We characterized the electrodes’ electrochemical performance via flow injection analysis 
coupled with amperometry. A 6-port valve actuator (Scivex, Oak Harbor, WA) was used for 
sample injection while a CHI832 bipotentiostat (CH Instruments, Inc., Austin, TX) was used for 
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electrochemical measurements. Two finger-tight fittings containing working electrodes were 
screwed into the sensor module’s sensor ports such that the electrodes were flush with the 
microfluidic channel. A saturated calomel reference electrode and platinum counter electrode were 
placed in a downstream waste beaker filled with 0.1 M potassium chloride (KCl). Initially, 0.1 M 
KCl was pumped through the device to establish a baseline current. Then, a 10 μL sample of 1 
mM ferrocene-trimethylamine (FcTMA+) in 0.1 M KCl was injected into the device, causing a 
change in current due to the oxidation and reduction of FcTMA+ at different working electrodes. 
This step was repeated several times after reestablishing the baseline current. 
3.3 Results and Discussion      
 The sensor module exhibited excellent sealing capabilities across all device 
designs/magnet arrangements and withstood backpressures as high as 322 kPa. Illustrated in Figure 
3.2, the burst pressure was significantly higher for devices designed with a gasket material 
compared to devices designed with a PDMS chip. One potential explanation for the difference in 
burst pressure between the two designs is that the PDMS chip has nearly 4 times more surface area 
than the gasket (0.86 in2 vs. 0.22 in2). While the magnets provide equal clamping force for both 
designs, the large surface area of the PDMS chip reduces the applied clamping pressure. Another 
potential explanation for the burst pressure difference is that the PDMS chip was cast in a 3D-
printed mold, resulting in surface irregularities that could reduce sealing effectiveness. Regardless 
of the design, the sensor module withstood higher backpressures compared to most previously 
reported microfluidic devices reversibly sealed with magnetic connections. Tkachenko et al., 
Abhyankar et al., and Rasponi et al. reported magnetic clamping systems for cell culture 
applications with burst pressures as high as 40 kPa, 35 kPa, and 58 kPa, respectively. Rafat et al. 
and Occhetta et al. reported devices with even higher burst pressures (145 kPa, 150 kPa). However, 
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all these devices were designed to clamp PDMS chips alone, whereas the sensor module is capable 
of clamping multiple materials. In addition to comparing the sensor module’s sealing effectiveness 
using different materials, we investigated whether different magnet arrangements provided more 
reliable seals. Higher burst pressures were seen in devices with magnets distributed equally around 
the perimeter (magnet arrangement 2), although the difference was not significant for gasketed 
devices. Magnet arrangement 2 provided more clamping force near the devices’ inlets and outlets 
where leakages typically occurred. Overall, any of the tested designs/magnet arrangements are 
suitable for OOC applications because the flow rates in OOC devices are typically an order of 
magnitude lower than the flow rates we used for leakage tests.  
To demonstrate that the sensor module can accommodate multiple electrochemical sensors 
simultaneously, we measured the oxidation and reduction of  FcTMA+ at different working 
Figure 3.2 Comparison of the average flow rates and corresponding burst pressures between different 
device designs and magnet arrangements. Burst pressures were significantly different between Gasket:1 
and PDMS:1; Gasket:2 and PDMS:2 (P < .01) as well as between PDMS:1 and PDMS:2 (P < .05). Burst 




electrodes with shared downstream reference and counter electrodes (Figure 3.3). After injecting 
samples into the device, FcTMA+  was oxidized at the upstream working electrode (WE1) with a 
perturbation voltage of +400 mV. Then, FcTMA2+ was reduced at the downstream working 
electrode (WE2) with a perturbation voltage of +200 mV. This shows that the working electrodes 
function independently despite sharing the same counter and reference electrodes. The first sample 
injection resulted in peak oxidation and reduction currents of 5.2e-7 A and -2.0e-7 A, respectively. 
Subsequent sample injections resulted in consistent peak oxidation and reduction currents of 6.5 ± 
0.1e-7 A and -2.4 ± 0.06e-7 A, respectively. To this point, we have only characterized FcTMA+ 
redox chemistry in the sensor module. However, our group has previously reported TPE’s with 
covalent surface modifications,35 thus opening the possibly to fabricate TPE-based biosensors that 
could be integrated into the sensor module. 
3.4 Conclusion 
 In conclusion, we designed and tested a microfluidic sensor module reversibly sealed with 
magnetic connections. The device could clamp both gaskets and PDMS chips with different 
magnet arrangements, enabling leak-free seals at high backpressures. Further, we integrated 
Figure 3.3 Electrochemical detection of ferrocene-trimethylamine (FcTMA+) redox chemistry. A) 
representative sensor module with two working electrodes in line with the microfluidic channel. B) 
Amperogram showing the repeated oxidation (blue peaks) and reduction (red peaks) of FcTMA+. 
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reusable TPEs into commercial finger-tight fittings and detected the oxidation/reduction of 
FcTMA+  at different working electrodes in the sensor module. Optical sensors could be integrated 
into finger-tight fittings by fixing polymeric thin films containing analyte sensitive dyes to the 
bottom of the fittings. The fitting’s hollow core would allow fiber optic probes to be easily aligned 
with the polymeric thin film. In the future, the sensor module will be implemented in OOC systems 
such as the previously reported microfluidic organotypic device (MOD)6 for real time sensing of 
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CHAPTER 4: CONCLUSION AND FUTURE DIRECTIONS 
 Since almost 95% of pharmaceutical drug candidates reaching clinical trials fail to gain 
market approval,1 there is a clear need for physiologically relevant ex vivo organ models to bridge 
the gap between in vitro and in vivo. OOC technologies have overcome many of the limitations 
associated with traditional in vitro culture models by incorporating physiological fluid flow and, 
in some cases, multiple cell types. However, most OOC devices rely on cell lines which fail to 
truly capture the complex anatomy and physiology of organs in vivo. The intestines are a 
particularly important organ to model ex vivo because they play a central role in human health and 
disease2 and is the primary organ that absorbs orally administered drugs.3 Designing a useful and 
reliable ex vivo intestinal model presents many challenges such as culturing viable explanted tissue 
for extended periods without blood supply, establishing and maintaining an oxygen gradient 
through the intestinal wall, and integrating sensors into microfluidic devices to detect physiological 
changes in real time. Perhaps the greatest challenge in designing an ex vivo intestinal model is 
maintaining diverse microbial populations on-chip that are representative of the adult human 
intestinal microbiome. Previous microfluidic intestinal models have included only a small subset 
of bacteria that inhabit the human gastrointestinal tract.4-9  
 This thesis describes the design and testing of 1) an instrumented microfluidic organotypic 
device (iMOD) for culture of murine intestinal tissue,10 and 2) a microfluidic sensor module to be 
implemented inline with the iMOD for real-time sensing of analytes and metabolites. In 
collaboration with Applied Medical Resources Corporation, we injection molded 200 iMODs that 
were used to culture full thickness murine intestinal explants for 72 hours ex vivo. Intestinal 
explants cultured in the iMOD formed a barrier between independent fluidic channels perfused 
with media, which is critical to recapitulating intestinal barrier function in vivo. We also 
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established differential oxygen concentrations in the fluidic channels and showed that more 
bacteria were present on the tissue’s mucosal surface when exposed to near-anoxic media. While 
the kinds of bacteria cultured in the iMOD were not characterized, 16S sequencing will be utilized 
in future studies to investigate microbial diversity. We also designed and tested a reversibly sealed 
microfluidic sensor module that could be implemented downstream of the iMOD in experiments 
requiring additional sensors. Importantly, the sensor module can be easily disassembled, and both 
the sensors and microfluidic device can be cleaned and reused. Future work will include 
developing electrochemical/optical sensors for various biological compounds (i.e. glucose, lactate, 
butyrate)  and integrating these sensors into the sensor module.  
 A crucial next step towards building a complete ex vivo intestinal model is to design and 
develop a scaled system comprising 1) pumps that supply culture media to multiple iMODs 
independently, 2) a custom manifold that holds multiple devices, 3) sensors to assess tissue health 
and monitor relevant analytes downstream of the explants in real-time, and 4) a fraction collector 
that stores effluent media in time resolved samples (Fig. 4.1). Thus far, we have designed initial 
prototypes of a multichannel peristaltic pump and a 48-well fraction collector. While several pump 
types have been implemented in OOC systems (i.e. pressure driven, syringe, gravity feed), 
peristaltic pumps are attractive because they are easily multiplexed, low cost, and enable flow rate 
control independent of a systems hydraulic resistance. However, peristaltic pumps often use 
silicone tubing that is highly oxygen permeable. A well-designed intestinal model requires near-
anoxic media delivery to the mucosal surface of intestinal explants. Therefore, tubing material is 
a critical peristaltic pump design parameter when oxygen concentrations need to be controlled. 
Culture media that is perfused through the iMOD and sensors module will ultimately be stored in 
a fraction collector to be analyzed at the conclusion of experiments. As previously mentioned, the 
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fraction collector is necessary because many analytes of interest will be quantified off-chip using 
analytical techniques like mass spectrometry and nuclear magnetic resonance. Real-time 
monitoring of certain analytes is unnecessary, yet the fraction collector allows for time-resolved 
sampling of effluent media. The automated fraction collector would also enable experimenters to 
track shifts in the metabolome over time while reducing manual labor. The proposed iMOD system 
(Fig. 4.1) would address major limitations to current OOC systems such as scalability, usability, 
and online sensing. We anticipate that the proposed system will be used for both basic research 
(i.e. disease modeling) and testing of new oral drugs. Ultimately, this technology will be 
implemented in long-term studies to elucidate the relationship among microbial, epithelial, neuro 




Figure 4.1 Scaled iMOD system consisting of anerobic and normoxic media pumps, iMOD unit (device 
and manifold), sensors module, and fraction collector. Dashed lines indicate the direction of media flow 
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APPENDIX: 2019 MICROTAS CONFERENCE PAPER 
Bridging the Gap: A Microfluidic Device for Studying Organotypic Barrier Tissues 
Summary 
Organ and tissue-on-a-chip technologies are powerful tools for drug discovery and disease 
modeling. However, many of these systems were not designed to recapitulate the intricate structure 
and function of native tissues. We developed a microfluidic device that supports full-thickness 
murine intestinal explants up to 72 h while maintaining differential oxygen across the tissue. The 
explants retained barrier properties for the duration of experiments, indicated by minimal trans-
tissue dye transfer. Further, we observed increased mucosal bacterial presence in explants cultured 
in a low oxygen environment. Incorporating cellularly heterogenous tissue into microfluidic 
devices with physiologically relevant environments is a key step in bridging the gap between in 
vitro and in vivo. 
Introduction 
Current Tissue-on-a-chip systems rely heavily on in vitro cell culture to create reductionist 
models of tissues and organs [1-3]. These systems recapitulate some tissue functions and are useful 
for high-throughput screening but fail to capture the richness of cell interactions of tissues in vivo 
because they lack the cellular diversity and complex architecture of native tissue. To bridge the 
gap between in vitro and in vivo models, some have incorporated tissue explants into microfluidic 
devices [4-7]. Progress has been made for many tissues, but integration of intestinal tissue into 
microfluidic devices ex vivo has remained challenging because it requires creating an oxygen 
gradient across the tissue to faithfully recreate the in vivo environment. Here, we report a 
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microfluidic device that supports differential flow with physiologically relevant oxygen 
concentrations over intestinal explants. 
Experimental 
 Instrumented microfluidic organotypic device (iMOD) prototypes were made using 
injection molding and consist of three cyclic olefin copolymer (COC) layers separated by 
polyurethane gaskets (Figure 1A). Intestinal tissue explants are housed in the middle layer with 
the mucosa and serosa facing independent microfluidic channels. Devices are assembled by 
stacking layers and snapping them together via integrated snap-fit fasteners. Glass coverslips fixed 
above and below the tissue enable on-chip imaging (Figure 1C,D) and visualization (Figure 1B). 
Dissolved oxygen concentrations (DOC) were measured using oxygen sensor spots adhered within 
Figure A1. Schematic illustration of the iMOD design and analysis of tissue health. (A) an exploded model 
of the iMOD system showing luminal (red) and serosal (blue) flow paths. B-C show stereotypic anatomical 
arrangement of gut wall at 0 h (B) and 72 h in low oxygen (C). D-E demonstrates stereotypic EtHD signal 
in colonic explants at apical most aspect of colonic crypts (arrows) at 0h (D) and 72 h in low oxygen (E). 
‘L’ denotes intestinal lumen, ‘m’ indicates mucosa, ‘sm’ submucosa, and ‘me’ muscularis externa.  Scale 
bars in A and B are 100 µm, scale bar in C is 50 µm, and scale bars in D-F are 25 µm. 
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the device (fluorescent quenching). Serum-free media was perfused in each channel at 250 μL/hr, 
to provide low shear stress across the tissue. 
Results and Discussion 
Mouse colon explants were cultured in the iMOD for 72 h ex vivo in both ambient and low 
mucosal DOC, maintaining intact tissue architecture, as marked by patterned rows of colonic 
crypts, interspersed lamina propria, and stereotypic arrangement of underlying submucosal and 
muscular layers (Figure 1B,C). Seen in Figure 1D,E, minimal cell death was observed, indicated 
by ethidium homodimer staining. Figure 2 shows that culture media perfused in each channel 
remained separated over 72 h, as demonstrated by the lack of fluorescein leakage across the tissue. 
Verification of media separation demonstrated that tissue explants maintained a physical barrier.  
Figure A2. Media was separated across channels as marked by fluorescein absorbance in effluent media. 
Mean absorbance (A.U.) at 488 nm wavelength demonstrates significantly more fluorescein presence in 
mucosal (circular points) effluents compared to serosal (square points) (P < 0.001).  No significant 
differences were observed across time in either the mucosal (P > 0.20) or serosal (P > 0.45) effluents. All 
statistical analyses were performed using a one-way ANOVA with α = .05. Representative images show 
visible green in mucosal (m) effluent compared to serosal (s) effluent. 
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We also demonstrated differential maintenance of bacteria on the tissue’s mucosal surface 
as a function of DOC (Figure 3). Fluorescent gram stain revealed increased bacterial presence on 
tissue perfused with media containing low DOC versus ambient DOC. To the authors’ knowledge, 
no other group has investigated differences in intestinal microbiota maintenance as a function of 
DOC in a microfluidic device. Ultimately, the iMOD supplemented with additional sensing 
functions will be implemented in long-term studies to elucidate the relationship among microbial, 
epithelial, neuro and immune components of the gut wall in health and disease. 
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Figure A3 Native microbiota were maintained in iMOD, and more bacteria were visible in an explant 
cultured in lower oxygen conditions. (A) Baseline bacterial levels are shown at 0h ex vivo via hexidium 
iodide (7.05 µM) fluorescence in red, signifying Gram-positive bacteria, and SYTO9 (5.01 µM) 
fluorescence in green, signifying Gram-negative bacteria.  Gram stain fluorescence was noticeably higher 
in tissue cultured in lowered oxygen conditions (B; 3 mmHg) when compared to tissue cultured in ambient 
oxygen (C; 100 mmHg) containing media. Scale bars in all panels are 100 µm. 
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APPENDIX B: COMPUTATIONAL MODEL OF INTESTINAL OXYGEN TRANSPORT 
WITHIN A MICROFLUIDIC ORGANOTYPIC DEVICE 
Introduction 
The in vivo intestinal environment features a steep oxygen gradient from lumen to serosa, 
which is essential for anaerobic bacteria and host tissue to survive. In the absence of blood flow, 
cultured intestinal explants require oxygen delivery via diffusion and convective transport in 
surrounding media. Previously, we cultured full thickness (~750 μm) murine intestinal explants in 
a microfluidic organotypic device (MOD) by perfusing media with low and ambient oxygen 
concentrations across mucosal and serosal surfaces, respectively.1 Here, we employ computational 
simulation to investigate oxygen distribution and consumption within intestinal tissue cultured in 
the MOD as a function of media flow rates and oxygen concentrations. These results, and those 
from future studies will influence design parameters for future MOD iterations such as channel 
dimensions and maximum tissue thickness. 
Methods 
A 3D computational model was created in COMSOL Multiphysics 4.4 by coupling the 
Laminar Flow and Transport of Diluted Species modules. Fluid flow  was governed by the steady-
state Navier-Stokes equations (eq. 1 and 2) assuming a Newtonian, incompressible fluid.                                        
                                (1)       
                                       (2)                                                                       
Here, u is the fluid velocity field, ρ is density, p is pressure, μ is dynamic viscosity, F is body 
forces, and ▽ is the del operator. Oxygen transport was governed by the steady-state convection-
diffusion equation (eq. 3) with a reaction term to account for tissue oxygen consumption. Here, Di 
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is the diffusion coefficient, ci is species concentration, and Ri is a reaction term. The convective 
velocity field (u) in eq. 3 was coupled to the velocity field calculated in the Laminar Flow module. 
In other words, convective oxygen transport resulted from fluid flow in the channels. Tissue 
oxygen consumption was modeled as a function of local oxygen concentration assuming first-
order Michaelis-Menten kinetics (eq. 4). Here, Ri is the oxygen consumption rate, Rmax is the 
maximum oxygen consumption rate, [c] is species concentration, Km is the Michaelis-Menten 
constant, and step(c) is a step function that terminates oxygen consumption when local 
concentrations fall below a specified value  Figure 4 shows the model schematic with 






Figure B1 Schematic of oxygen transport and fluid flow in the iMOD. Laminar flow, convective and 
diffusive oxygen transport occur in the fluid channels whereas diffusive oxygen transport and oxygen 
consumption occur in the tissue explant.  
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Boundary/Initial Conditions and Model Parameters   
Two boundary conditions were applied to the fluid inlets: 1) laminar inflow with flow rates 
that ranged from 2.5-10 mL/h, and 2) mass inflow of dissolved oxygen at a concentration of 20% 
for the serosal channel and 0.5-2.5% for the luminal channel. Two boundary conditions were also 
applied to the fluid outlets: 1) laminar outflow with an exit pressure of 1 atm, and 2) mass outflow. 
A no flux boundary condition was applied to all other surfaces excluding the tissue-channel 
interfaces. Initial oxygen concentrations for the tissue, serosal channel, and luminal channel were 
7%, 20%, and 0.5-2.5%, respectively. Model parameters are summarized in Table 1. 
 
Results and Discussion 
 As shown in Figure 2, higher flow rates resulted in a steeper oxygen gradient within the 
tissue due to convective oxygen transport to the tissue’s serosal surface. For all flow rates, 
dissolved oxygen concentrations (DOC) in the Luminal and Serosal channels were set at 0.5% and 
Table B1 Model parameter values 
Parameter Description Value










Rmax Max O2 consumption rate - 0.001 [mol/m
3
/s]
Km Michaelis-Menten constant 0.011 [mol/m
3
]
coff O2 concentration at which O2 consumtion is terminated 0.001 [mol/m
3
]
ρtissue Density of intestinal tissue 1088 [kg/m3]
ρmedia Density of culture media (37° C) 993 [kg/m3]
μ Dynamic viscosity of culture media (37° C) 6.9 x 10-4 [Pa.s]
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Figure B2 Oxygen concentration profiles with varying Luminal (upper channel, 
0.5% O2) and Serosal (lower channel, 20% O2) media flow rates. A) Flow rate = 
2.5mL/h. B) Tissue O2 concentration with flow rates of 2.5 mL/h and 10 mL/h. C) 
Flow rate = 10mL/h. Arrows show direction and magnitude of velocity; dashed 
vertical lines in A and C show location where data for B was obtained. 
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20%, respectively. DOC at the serosal surface, center of the tissue, and mucosal surface were 
[9.6%, 2.8%, 0.84%] and [13%, 4.5%, 1.2%] for flow rates equal to 2.5 mL/h and 10 mL/h, 
respectively. The differences in DOC between flow rates were most pronounced at the tissue’s 
serosal surface because most of the oxygen that diffused through the tissue was consumed before 
reaching the tissue’s mucosal surface. In vivo, intestinal oxygen concentrations are ~7-10% in the 
muscular wall,2 ~ 6% in the vascularized submucosa,2 and  <  ~2% in the epithelial cell layer 
(Zheng 2015). While a flow rate of 10 mL/h resulted in a higher than average serosal DOC, the 
submuscosal and mucosal DOC more closely reflected in vivo conditions.  
 We also computed the tissue oxygen gradient as a function of luminal DOC. In this study, 
both the luminal (0.5%, 1.5%, 2.5% O2) and serosal (20% O2) channels were perfused at a flow 
rate of 10 mL/h. Illustrated in Figure 3, DOC at the serosal surface, center of the tissue, and 
mucosal surface were [13%, 4.5%, 1.2%], [13%, 4.9%, 1.9%], and [13%, 5.2%, 2.6%] for luminal 
DOC of 0.5%, 1.5%, and 2.5%, respectively. As expected, the difference in DOC were greatest at 
the tissue’s mucosal surface because only the luminal DOC was varied. While mucosal DOC were 
higher with increased luminal DOC, anaerobic bacteria require near-anoxic conditions to survive. 
Therefore, 1.5% and 2.5% Luminal DOC may be unsuitable for culturing diverse microbial 
populations in the iMOD. One limitation of this model is that oxygen consumption by obligate 
aerobes, facultative anaerobes, and microaerophiles inhabiting the luminal channel is not 
accounted for. Future studies may indicate that bacterial oxygen consumption in the luminal 





 Future extensions of this model could include parameterizing channel dimensions, serosal 
DOC, tissue thickness, and tissue oxygen consumption rates. Additionally, bacterial oxygen 
consumption in the luminal channel could accounted for. Long term, the iMOD will be used to 
study interactions among the microbial-epithelial-immune-neural components that comprise the 
barrier along the gastrointestinal tract. Future modeling experiments will help dictate the 
parameters of tissue explant studies performed using the iMOD. 
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Figure B3 Tissue oxygen gradients as a function of luminal dissolved oxygen concentration. Dashed lines 
indicate the serosal and mucosal surfaces of the tissue. Flow rate = 10 mL/h. 
